What does the clinical evidence show about GHK-Cu, BPC-157, and TB-500 in humans?

The three compounds sit at very different points on the evidence scale, and none stands where its marketing implies. GHK-Cu, a copper-bound tripeptide first isolated from human plasma in the 1970s, carries the most human data, though that record is a small set of dermatology studies; BPC-157's literature is almost entirely rodent work from a single group with no retrievable human efficacy trial; and the rigorous trials cited for TB-500 were run on a different molecule, full-length thymosin beta-4.

How much published human trial data exists for topical GHK-Cu, and what did those studies measure?

Counted honestly, the human record for topical GHK-Cu is a handful of studies rather than a body of literature. The most cited are facial-cream evaluations from the late 1990s and early 2000s, generally 20 to 70 subjects over 8 to 12 weeks, and the studies with the most rigorous endpoints are the smallest ones.

• Objective endpoints: High-frequency ultrasound for skin density, silicone-replica profilometry for wrinkle depth, and punch-biopsy histology for collagen.
• 1998 Abdulghani biopsy study: A copper-peptide cream against tretinoin, vitamin C, and melatonin in roughly 20 subjects, reporting increased collagen production.
• Leyden evaluations: Reported wrinkle and skin-density gains, but appeared as dermatology-conference posters rather than peer-reviewed full papers.
• 1994 Mulder trial: Topical GHK-Cu gel produced faster diabetic-foot-ulcer closure than vehicle, a real clinical endpoint rather than a proxy.

Is there any completed randomized controlled trial of BPC-157 in people?

No completed, published, peer-reviewed randomized controlled efficacy trial of BPC-157 in humans is retrievable, which is worth stating plainly because most writing on the compound implies otherwise. Its literature runs to hundreds of papers, but the overwhelming majority comes from one University of Zagreb group and is almost entirely rat and mouse work. Claims that it cleared phase I and entered phase II for inflammatory bowel disease circulate widely, yet they trace to no publicly retrievable trial report.

1. 2022: WADA prohibited BPC-157 under the S0 non-approved-substances class, effective 1 January.
2. 2023: The FDA placed BPC-157 in Category 2 of the 503A bulk drug substances list, the bucket for substances with significant safety concerns.
3. By April 2026: The nomination was withdrawn by its nominators, so BPC-157 no longer sits in Category 2, though the agency still records that it lacks sufficient information to know whether the drug would cause harm.

Do the human trials often cited for TB-500 actually test TB-500, or a different molecule?

The human trials routinely cited for TB-500 tested a different molecule, and that single substitution is the most consequential error in how the peptide is discussed. Thymosin beta-4 is a naturally occurring 43-amino-acid protein; TB-500 is a short synthetic peptide built around its actin-binding motif, commonly the seven-residue LKKTETQ region in acetylated form. A fragment carries different size, pharmacokinetics, and tissue distribution, with no obligation to reproduce the parent protein's full activity profile.

What methodological weaknesses limit what the existing human studies can prove?

The existing human studies were built to generate a signal, not to settle a question, and several structural limits cap what they can prove. Sample size is the first and most underestimated: a 12-week study in 30 subjects detects only a large effect and characterizes only the most common short-term reactions.

1. Sample size: A 30-subject, 12-week study is underpowered for a modest effect and cannot support subgroup claims.
2. Venue: Conference posters and cosmeceutical book chapters omit the randomization method, blinding, and dropout accounting.
3. Affiliation: Industry-funded studies report favorable conclusions substantially more often; several copper-peptide papers and the BPC-157 corpus carry that tie.
4. Endpoint softness: Subject visual grading of wrinkles is among the least reliable measurements in dermatology.
5. Missing integrity scaffolding: No preregistered protocol, prespecified primary endpoint, or published statistical analysis plan.
6. Short follow-up: Twelve weeks says nothing about a year of continuous use, cumulative exposure, or whether an early change reverses.

What is known about safety and adverse effects in people, as opposed to efficacy?

Safety and efficacy are separate questions with separate evidence, and the safety record is thinner than commonly assumed even where efficacy has something to show. Absence of detected harm in a small, short study is not evidence of safety; it is absence of evidence.

• GHK-Cu and thymosin beta-4: Reported mild, transient local effects and acceptable tolerability across several hundred monitored participants.
• BPC-157: No adequately powered human safety data; the FDA's 2023 Category 2 placement flagged insufficient characterization, not proven harm.
• Shared theoretical concern: Compounds selected for angiogenesis, cell migration, and proliferation act on the same machinery a tumor uses, and no human record is long enough to resolve it.
• Supply-chain risk: Independent analyses of research-chemical peptides have repeatedly found contents that do not match the label.

Why do strong results in rodent studies so often fail to reproduce in humans?

Roughly 90 percent of drug candidates that clear preclinical testing fail once they reach human trials, most often for lack of efficacy rather than toxicity, so an impressive rodent result is the start of the question rather than its answer. The reproducibility record underneath is worse still, and it is the number most often skipped.

If the three were ranked by strength of human evidence, how would they order?

Ranked by the quantity and quality of human evidence, the order runs GHK-Cu first, thymosin beta-4 second, and BPC-157 a distant third, with the asterisk that thymosin beta-4 is not the molecule sold as TB-500. The ranking measures how much has been looked for, not how well anything works.

How do regulators and anti-doping bodies treat each of these three compounds?

The three compounds occupy very different legal categories, and the differences reflect legal lane as much as science. Cosmetic status is a marketing lane rather than a verdict on whether something works, and a prohibition can reflect a plausible performance effect in an untested compound rather than a demonstrated one.

• GHK-Cu: Circulates as the cosmetic ingredient copper tripeptide-1, facing no premarket approval and barred from structure-or-function claims without becoming an unapproved drug.
• BPC-157: Holds no approval in any jurisdiction; withdrawn from 503A Category 2 by April 2026 but still off the bulks list, leaving it outside lawful compounding-pharmacy use.
• WADA prohibitions: BPC-157 banned under class S0 since 1 January 2022; thymosin beta-4 and its named derivative TB-500 prohibited at all times under the growth factors class.